SEBI approves Piramal Pharma’s Rs 1,050-crore rights issue
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
First of its kind screening for Glaucoma at grass root level over 10k screened already
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Cipla has a robust governance model focused on sustainability
Subscribe To Our Newsletter & Stay Updated